Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differentiation and definition of vascular-targeted therapies.
Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marmé D, Lorusso PM. Siemann DW, et al. Among authors: marme d. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):416-20. Clin Cancer Res. 2005. PMID: 15701823 Review.
PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
Drevs J, Müller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, Wood J, Hennig J, Unger C, Marmé D. Drevs J, et al. Among authors: marme d. Cancer Res. 2002 Jul 15;62(14):4015-22. Cancer Res. 2002. PMID: 12124335
The impact of anti-angiogenic agents on cancer therapy.
Marmé D. Marmé D. J Cancer Res Clin Oncol. 2003 Nov;129(11):607-20. doi: 10.1007/s00432-003-0488-9. Epub 2003 Sep 16. J Cancer Res Clin Oncol. 2003. PMID: 13680378 Review. No abstract available.
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marmé D, Steward WP. Morgan B, et al. Among authors: marme d. J Clin Oncol. 2003 Nov 1;21(21):3955-64. doi: 10.1200/JCO.2003.08.092. Epub 2003 Sep 29. J Clin Oncol. 2003. PMID: 14517187 Clinical Trial.
143 results